Identification of DLC‑1 expression and methylation status in patients with non‑small‑cell lung cancer

Feng,Hongxiang; Zhang,Zhenrong; Wang,Xiaowei; Liu,Deruo

doi:10.3892/mco.2015.681

Identification of DLC‑1 expression and methylation status in patients with non‑small‑cell lung cancer

Authors:
- Hongxiang Feng
- Zhenrong Zhang
- Xiaowei Wang
- Deruo Liu
View Affiliations

Affiliations: Department of Thoracic Surgery, China‑Japan Friendship Hospital, Beijing 100029, P.R. China
Published online on: November 20, 2015 https://doi.org/10.3892/mco.2015.681
Pages: 249-254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In order to determine whether the deleted in liver cancer‑1 (DLC‑1) gene is deregulated in non‑small‑cell lung carcinoma (NSCLC) and to assess the contribution of molecular alterations in DLC‑1 to lung carcinogenesis, a total of 84 tissue specimens (30 NSCLC and 30 corresponding adjacent normal tissues; 5 benign tumor and 5 corresponding adjacent normal tissues; and 10 pulmonary bullae and 4 corresponding adjacent normal tissues), were obtained from 45 patients who underwent curative surgical resection. DLC‑1 mRNA expression was evaluated by reverse transcription‑quantitative polymerase chain reaction (PCR) and its protein level was assessed by western blot analysis. A significant downregulation of DCL‑1 at the mRNA and protein levels was observed in NSCLC tissues when compared to benign lung tumors and normal lung tissues (P<0.001). To further determine whether the decreased expression of DLC‑1 at the mRNA and protein levels is associated with the methylation of its promoter, methylation‑specific PCR was performed following extraction of genomic DNA from the samples. DLC‑1 promoter methylation was identified in 7 of the 30 (23.3%) NSCLC tissue samples, but not in the corresponding adjacent normal tissues from NSCLC patients or in lung tissues from non‑NSCLC patients. Our data indicated that DLC‑1 hypermethylation may play a crucial role in lung carcinogenesis and may be a target for the treatment of NSCLC.

View Figures

View References

1	Song F, He M, Li H, Qian B, Wei Q, Zhang W, Chen K and Hao X: A cancer incidence survey in Tianjin: the third largest city in China-between 1981 and 2000. Cancer Causes Control. 19:443–450. 2008. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
3	Pike BL, Greiner TC, Wang X, Weisenburger DD, Hsu YH, Renaud G, Wolfsberg TG, Kim M, Weisenberger DJ, Siegmund KD, Ye W, Groshen S, Mehrian-Shai R, Delabie J, Chan WC, Laird PW and Hacia JG: DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia. 22:1035–1043. 2008. View Article : Google Scholar : PubMed/NCBI
4	García P, Manterola C, Araya JC, Villaseca M, Guzman P, Sanhueza A, Thomas M, Alvarez H and Roa JC: Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Mol Carcinog. 48:79–89. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kim TY, Jong HS, Song SH, Dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M and Bang YJ: Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene. 22:3943–3951. 2003. View Article : Google Scholar : PubMed/NCBI
6	Wong CM, Lee JM, Ching YP, Jin DY and Ng IO: Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 63:7646–7651. 2003.PubMed/NCBI
7	Teramoto A, Tsukuda K, Yano M, Toyooka S, Dote H, Doihara H and Shimizu N: Less frequent promoter hypermethylation of DLC-1 gene in primary breast cancers. Oncol Rep. 12:141–144. 2004.PubMed/NCBI
8	Song YF, Xu R, Zhang XH, Chen BB, Chen Q, Chen YM and Xie Y: High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J Clin Pathol. 59:947–951. 2006. View Article : Google Scholar : PubMed/NCBI
9	Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene. 23:1405–1411. 2004. View Article : Google Scholar : PubMed/NCBI
10	Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, Zender L and Lowe SW: DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev. 22:1439–1444. 2008. View Article : Google Scholar : PubMed/NCBI
11	Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, Hofmann HS, Silber RE, Burdach S and Hansen G: CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer. 41:1223–1236. 2005. View Article : Google Scholar : PubMed/NCBI
12	Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest. 111:1710–1717. 1997. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−∆∆CT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Castro M, Grau L, Puerta P, Gimenez L, Venditti J, Quadrelli S and Sánchez-Carbayo M: Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in lung cancer. J Transl Med. doi: 10.1186/1479-5876-8-86.
15	Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, Rha SY, Tan J, Hsieh WS, Ambinder RF, Lin X, Chan AT and Tao Q: The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene. 26:934–944. 2007. View Article : Google Scholar : PubMed/NCBI
16	Kikuchi S, Yamada D, Fukami T, Masuda M, Sakurai-Yageta M, Williams YN, Maruyama T, Asamura H, Matsuno Y, Onizuka M and Murakami Y: Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell lung cancer. Clin Cancer Res. 11:2954–2961. 2005. View Article : Google Scholar : PubMed/NCBI
17	Shopland DR, Eyre HJ and Pechacek TF: Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst. 83:1142–1148. 1991. View Article : Google Scholar : PubMed/NCBI
18	Kim DH, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ and Kelsey KT: p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 61:3419–3424. 2001.PubMed/NCBI
19	Jarmalaite S, Kannio A, Anttila S, Lazutka JR and Husgafvel-Pursiainen K: Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer. 106:913–918. 2003. View Article : Google Scholar : PubMed/NCBI
20	Kim DH, Kim JS, Ji YI, Shim YM, Kim H, Han J and Park J: Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res. 63:3743–3746. 2003.PubMed/NCBI
21	Kikuchi S, Yamada D, Fukami T, Maruyama T, Ito A, Asamura H, Matsuno Y, Onizuka M and Murakami Y: Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma. Cancer. 106:1751–1758. 2006. View Article : Google Scholar : PubMed/NCBI
22	Toyooka S, Maruyama R, Toyooka KO, McLerran D, Feng Z, Fukuyama Y, Virmani AK, Zochbauer-Muller S, Tsukuda K, Sugio K, Shimizu N, Shimizu K, Lee H, Chen CY, Fong KM, Gilcrease M, Roth JA, Minna JD and Gazdar AF: Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer. 103:153–160. 2003. View Article : Google Scholar : PubMed/NCBI
23	Peto R, Darby S, Deo H, Silcocks P, Whitley E and Doll R: Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ. 321:323–329. 2000. View Article : Google Scholar : PubMed/NCBI
24	Hussain SP and Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 121:2373–2380. 2007. View Article : Google Scholar : PubMed/NCBI
25	Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M and Ushijima T: High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 12:989–995. 2006. View Article : Google Scholar : PubMed/NCBI
26	Belinsky SA, Nikula KJ, Baylin SB and Issa JP: Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc Natl Acad Sci USA. 93:4045–4050. 1996. View Article : Google Scholar : PubMed/NCBI
27	Vertino PM, Yen RW, Gao J and Baylin SB: De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol. 16:4555–4565. 1996. View Article : Google Scholar : PubMed/NCBI